World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   17 records for 5 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1
Recruitment statusMain ID Public TitleDate of Registration
Not RecruitingCTRI/2014/09/004959
A clinical trial to compare safety and efficacy of two formulations of Rituximab, both being administered in combination with CHOP chemotherapy regimen, in patients with Diffuse Large B-Cell Lymphoma (DLBCL)
02-09-2014
RecruitingNCT01915303
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2013-002170-49-DEA Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing’s disease17/09/2013
AuthorisedEUCTR2013-002170-49-ESA Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing?s disease12/11/2013
AuthorisedEUCTR2013-002170-49-HUA Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing’s disease13/12/2013
AuthorisedEUCTR2013-002170-49-GRA Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing’s disease24/01/2014
AuthorisedEUCTR2013-002170-49-ITStudy of the efficacy and safety of pasireotide s.c. +/- cabergoline in patients with Cushing’s disease22/10/2013
AuthorisedEUCTR2013-002170-49-BEA Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing’s disease04/12/2013
AuthorisedEUCTR2013-002170-49-NLA phase 2 trial to find out if treating patients that suffer Cushing's disease with pasireotide and cabergoline is safe and efficacious17/12/2014
Not RecruitingCTRI/2014/06/004700a study to find out if a drug pasireotide used alone or used with cabergoline together is safe and beneficial for patients with Cushingâ??s disease(Cushingâ??s disease is a condition where the pituitary gland releases too much adrenocorticotropic hormone (ACTH).24-06-2014
10/06/2013
Not recruitingNCT01866904
Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable CAD in Post MI Patients
Recruitment statusMain IDPublic titleDate of registration
Not RecruitingCTRI/2013/08/003931To provide long term data from clinical practices in treatment of Myocardial Infarction patients with stable coronary artery disease.29-08-2013
29/05/2013
Not RecruitingCTRI/2013/02/003380
This study is to survey on venous thromboembolism risk in cancer patients (lung or colorectal) who were about to start a new chemotherapy regimen.
12-02-2013
Not RecruitingCTRI/2013/01/003333
An observational registry to evaluate the current clinical practice on the management of diarrhea in children
28-01-2013
RecruitingNCT01712438
Human-cl-rhFVIII in Previously Untreated Patients
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2012-002554-23-ESThe ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.06/03/2013
AuthorisedEUCTR2012-002554-23-FRThe ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.02/04/2014
AuthorisedEUCTR2012-002554-23-PTThe ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.30/07/2014
RecruitingISRCTN50040185NuProtect: Immunogenicity, efficacy and safety of treatment with Human-cl rhFVIII in previously untreated patients with severe haemophilia A22/10/2013
AuthorisedEUCTR2012-002554-23-DEThe ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.26/02/2013
AuthorisedEUCTR2012-002554-23-GBThe ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.13/02/2013
RecruitingCTRI/2013/09/003958A clinical trial to study Immunogenicity, Efficacy and Safety of Treatment with Human-cl rhFVIII in Previously Untreated Patients with Severe Haemophilia A05-09-2013
18/10/2012
RecruitingNCT01610037
Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2012-002057-38-SIComparison of long-term safety of the combination product QVA149A against placebo and standard of care treatment in Chronic Obstructive Pulmonary Disease patients with moderate to severe airflow limitation18/06/2012
AuthorisedEUCTR2012-002057-38-HUComparison of long-term safety of the combination product QVA149A against placebo and standard of care treatment in Chronic Obstructive Pulmonary Disease patients with moderate to severe airflow limitation16/07/2012
AuthorisedEUCTR2012-002057-38-GBComparison of long-term safety of the combination product QVA149A against placebo and standard of care treatment in Chronic Obstructive Pulmonary Disease patients with moderate to severe airflow limitation16/07/2012
Not RecruitingEUCTR2012-002057-38-PLComparison of long-term safety of the combination product QVA149A against placebo and standard of care treatment in Chronic Obstructive Pulmonary Disease patients with moderate to severe airflow limitation07/09/2012
Not RecruitingEUCTR2012-002057-38-LVComparison of long-term safety of the combination product QVA149A against placebo and standard of care treatment in Chronic Obstructive Pulmonary Disease patients with moderate to severe airflow limitation22/08/2012
Not RecruitingEUCTR2012-002057-38-EEComparison of long-term safety of the combination product QVA149A against placebo and standard of care treatment in Chronic Obstructive Pulmonary Disease patients with moderate to severe airflow limitation06/09/2012
Not RecruitingCTRI/2012/12/003207Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in COPD Patients With Moderate to Severe Airflow Limitation12-12-2012
30/05/2012
Not recruitingNCT01544920
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755) 28/02/2012
Not RecruitingCTRI/2012/02/002407
"IDMPS will be an international, multicenter, observational study with a cross-sectional study to assess current practices in the management in the patients with type 1 and type 2 diabetes mellitus non-interventional on therapeutic strategy"
07-02-2012
Not RecruitingEUCTR2011-001062-18-GR
A clinical trial looking at the effect of different doses of QAW039 in patients with moderate or severe allergic asthma
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2011-001062-18-GBDose finding study for QAW039 in asthma.27/07/2011
Not RecruitingEUCTR2011-001062-18-BGDose Finding Study for QAW039 in Asthma 29/06/2012
Not RecruitingEUCTR2011-001062-18-PLA clinical trial looking at the effect of different doses of QAW039 in patients with moderate or severe allergic asthma18/11/2011
Not RecruitingEUCTR2011-001062-18-NLDose Finding Study for QAW039 in Asthma 29/05/2012
Not RecruitingEUCTR2011-001062-18-ATDose Finding Study for QAW039 in Asthma 28/07/2011
Not RecruitingEUCTR2011-001062-18-ITDose Finding Study for QAW039 in Asthma12/06/2012
Not RecruitingEUCTR2011-001062-18-HUDose Finding Study for QAW039 in Asthma15/09/2011
Not recruitingNCT01437735Dose Finding Study for QAW039 in Asthma14/09/2011
Not RecruitingCTRI/2011/12/002279Study conducted to find Dose of the Study medication QAW039 in Asthma23-12-2011
11/07/2011
    
1
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.2 - Version history